Passage Bio (PASG): Director received 11K units
Dolan Sondhi, Director at Passage Bio, reported a grant / award of 11K units.
- 11K
- Derivative units
- Traded
- May 19, 2026
- Filed
- May 22, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- May 21, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
- Jun 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedControl of the company changed hands, and changed a top executive or board member (and 5 more items)“On June 24, 2026, Passage Bio and Remix issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference.”
- Jun 25, 2026Insider10% owner purchased ~$206K of PASG shares in the open market
- Sep 2, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Passage Bio
OQRO holds no insider, Congress, fund or contract record for Passage Bio dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PASG page.
How this filing works
Explore the data
Common questions
Which Passage Bio (PASG) insider traded, and how much?
Dolan Sondhi, Director at Passage Bio, reported a grant / award of 11K units. Not an open-market trade.
When did it happen, and when was it made public?
Traded: May 19, 2026. Filed: May 22, 2026. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean PASG stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Passage Bio
- SEC Form 4Jun 30, 2026
- SEC Form 4Jan 13, 2026
- SEC Form 4Jan 13, 2026
- SEC Form 4Sep 16, 2025
- SEC Form 4Sep 16, 2025
- SEC Form 4Sep 16, 2025
Everything OQRO holds on this company is on its PASG page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data